Skip to main content

Table 2 Characteristics of the antibody-positive patients

From: Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY

 

Age (y.)

Mutation

ERT

Ab Titer ag. alfa

Ab Titer ag. beta

IgG1

IgG2

IgG3

IgG4

RRA alfa

RRA beta

lysoGb3 (ng/ml)

Renal event

Clinical phenotype

MSSI

Exposure

Total

Cardio-vasc

General

Neuro

Renal

Type

Time (months)

1 M

43.8

c.233C>G

p.Ser78*

B

182.0

1,638,400

1,638,400

++++

++++

++++

++++

4%

1%

41.0

yes

Classic

45

15

7

5

18

2 M

33.4

c.847C>T

p.Gln283*

B

159.3

1,638,400

1,638,400

+++

++++

++++

++++

42%

32%

48.0

 

Classic

14

9

2

3

0

3 M

47.7

c.522T>A

p.Cys174*

B

3.2

1,638,400

1,638,400

++++

+++

+++

+

20%

17%

21.7

 

Classic

12

0

4

0

8

4 M

46.1

c.901C>T

p.Arg301*

A

78.2

819,200

819,200

++++

++++

++++

++++

41%

35%

60.0

 

Classic

28

3

11

14

0

5 M

33.2

c.548G>C

p.Gly183Ala

A/B

157.4

1,638,400

1,638,400

++++

++++

+

++++

20%

20%

76.0

 

Classic

11

0

9

2

0

6 M

43.3

c.169C>T

p.Gln57*

A/B

170.4

819,200

819,200

++++

++++

++++

++++

3%

4%

31.3

yes

Classic

45

17

4

6

18

7 M

47.3

c.847C>T

p.Gln283*

B

156.2

819,200

819,200

++++

++++

++

++++

46%

36%

25.4

 

Classic

12

10

2

0

0

8 M

50.6

c.802-3_802-2del

unknown

B

16.0

204,800

204,800

++++

++

+++

++++

98%

76%

na

 

Classic

38

18

5

7

8

9 M

32.7

c.884T>G

p.Phe295Cys

B

46.6

102,400

102,400

++++

no

no

no

mig

mig

10.0

yes

Classic

29

0

2

9

18

10 M

59.1

c.758T>C

p.Ile253Thr

A

7.8

102,400

102,400

++++

no

++

++

75%

61%

10.8

 

Non classic

23

13

1

1

8

11 M

17.5

c.902G>A

p.Arg301Gln

B

5.1

102,400

102,400

++++

++

+

++++

40%

29%

NA

 

Classic

14

0

6

8

0

12 M

27.7

c.901C>T

p.Arg301*

A/B

69.3

25,600

12,800

+++

+++

++

++++

54%

38%

48.8

 

Classic

19

2

6

11

0

13 M

52.1

c.798T>A

p.Asp266Glu

A/B

116.1

12,800

12,800

++++

++

++

no

99%

103%

na

yes

Classic

34

0

8

8

18

14 M

49.8

c.847C>T

p.Gln283*

B

133.5

1600

1600

++++

+

+

no

144%

115%

84.2

yes

Classic

31

7

4

2

18

15 M

41.1

c.1069_1079del

p.Gln357Trpfs*14

A/B

146.3

800

800

no

no

+++

++++

142%

100%

18.9

 

Classic

24

2

9

5

8

16 M

31.9

c.875C>T

p.Ala292Val

A

135.7

800

800

+++

no

++

++++

114%

93%

15.0

 

Classic

8

3

2

3

0

17 M

51.0

c.798T>A

p.Asp266Glu

A

120.5

400

400

+

no

no

no

136%

106%

na

yes

Classic

33

0

5

10

18

18 M

27.9

c.729G>C

p.Leu243Phe

A/B

151.0

100

100

no

no

++

no

141%

110%

na

 

Classic

18

0

4

14

0

19F

65.3

c.695T>C

p.Ile232Thr

A

1.8

6400

6400

no

no

+

no

120%

110%

1.5

 

NA

19

15

4

0

0

20F

43.2

c.486G>C

p.Trp162Cys

B

10.2

12,800

50

+

no

no

no

126%

113%

4.3

 

NA

13

0

1

8

4

  1. RRA was considered not informative in the patient #9 under migalastat (mig)
  2. M males, F female, A agalsidase alfa, B agalsidase beta, na not available, NA not applicable; Ab titers observed against agalsidase alfa (ag. alfa) or beta (ag. beta); Renal event defined as estimated glomerular filtration rate below 15 ml/min/1.73m2 and/or kidney transplant and/or dialysis; MSSI Mainz Severity Score Index with total, cardiovascular (cardio-vasc), general, neurological (neuro) and renal scores
  3. *Non-sense mutations